TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16036193

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of a mixture of 10 mL of 0.5% bupivacaine (50 mg) with epinephrine (1:500) in 40 mL of Ringer's lactate solution postoperatively (Group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: The same mixture solution infusion preoperatively and postoperatively (total 100 mg bupivacaine) (Group B)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 91
Study: 12360599

Group type: EXPERIMENTAL
Intervention: Group 1: Omeprazol, Fromilid (clarithromycin), and Metronidazol for 7 days followed by 2-week Omeprazol alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group 2: Omeprazol, Fromilid (clarithromycin), and Furasolidon for 7 days followed by 2-week Omeprazol alone
Number of subjects: 20
Study: 10825867

Group type: EXPERIMENTAL
Intervention: Opalescence (10% carbamide peroxide gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NiteWhite Excel (10% carbamide peroxide gel)
Number of subjects: 0
Study: 7578781

Group type: EXPERIMENTAL
Intervention: Fixed bridge between the distal tooth of the residual dentition and an implant
Number of subjects: 23

Group type: COMPARATOR
Intervention: Free-standing bridge on 2 implants
Number of subjects: 23

Group type: COMPARATOR
Intervention: Implant-supported bridges
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tooth-implant fixed bridges
Number of subjects: 23
Study: 2154154

Group type: EXPERIMENTAL
Intervention: MDI (4 puffs, 800 micrograms of radiolabeled fenoterol)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Jet nebulizer (1.75 ml, 1,750 micrograms of radiolabeled fenoterol solution)
Number of subjects: 21
Study: 6814282

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with two timothy major allergens, 19, 25, or partially purified timothy extract
Number of subjects: 40
Study: 31438986

Group type: EXPERIMENTAL
Intervention: Tocilizumab 12 mg/kg IV every 2 weeks (Q2W)
Number of subjects: 11
Study: 28177691

Group type: EXPERIMENTAL
Intervention: Caffeine 2.5 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine 5.0 mg/kg
Number of subjects: 10
Study: 26505184

Group type: EXPERIMENTAL
Intervention: Train-the-trainer workshops (TTT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Written implementation guideline (GL)
Number of subjects: 10
Study: 23720124

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intra-articular injection with local corticosteroids
Number of subjects: 51
Study: 21540198

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Canakinumab 100 mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Canakinumab 200 mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Canakinumab (50+50+25+25 mg)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Colchicine 0.5 mg
Number of subjects: 432
Study: 19735403

Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope
Number of subjects: 10

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 10
Study: 17517066

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1122
Study: 16413334

Group type: EXPERIMENTAL
Intervention: Low-dose abdominal computed tomography (LDCT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Abdominal plain film (APF)
Number of subjects: 139
Study: 15205246

Group type: EXPERIMENTAL
Intervention: Brimonidine purite 0.15% given twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dorzolamide 2% given twice daily
Number of subjects: 33
Study: 11087239

Group type: EXPERIMENTAL
Intervention: Doxazosin administration (subgroup 1B, n = 7)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: No doxazosin administration (subgroup 1A, n = 7)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonsmokers (group 2, n = 10)
Number of subjects: 24
Study: 8922160

Group type: EXPERIMENTAL
Intervention: Heparin infusion for 12 to 18 hours after intervention
Number of subjects: 4010

Group type: COMPARATOR
Intervention: No heparin infusion
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Arterial sheath removal 12 to 18 hours after angioplasty
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Arterial sheath removal more than 18 hours after angioplasty
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Transfer to ICU after angioplasty
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Use of CareMAPs or care plans for standardization of care
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Complete bed rest for patients after angioplasty
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Bed rest for an additional 6 hours after sheath removal
Number of subjects: 4010
Study: 1343613

Group type: EXPERIMENTAL
Intervention: 40 mg b.i.d. lovastatin (Mevacor)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 4052861

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine/2% lidocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine/2% lidocaine/1:100 000 epinephrine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 31144304

Group type: EXPERIMENTAL
Intervention: PPARÎ´ agonist GW501516
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPARÎ´ antagonist GSK0660
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palmitic acid (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DHFR siRNA or methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: EC-specific Ppard knockout
Number of subjects: 0
Study: 28794207

Group type: EXPERIMENTAL
Intervention: DI + walking (2.5 h/wk)
Number of subjects: 82

Group type: COMPARATOR
Intervention: DI only
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DI + walking
Number of subjects: 82
Study: 26291962

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 46
Study: 23863754

Group type: EXPERIMENTAL
Intervention: Ritualistic behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritualistic gestures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritual with delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performing a ritual oneself
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituals
Number of subjects: 0
Study: 21751945

Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09%
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 20359087

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea syndrome (OSAHS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Habitual snoring
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea syndrome (OSAHS) with abnormal behavior
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Habitual snoring with abnormal behavior
Number of subjects: 110
Study: 17465970

Group type: EXPERIMENTAL
Intervention: Naproxen 10 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Paracetamol 20 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg i.v.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Naproxen, Paracetamol, and Placebo with Pethidine
Number of subjects: 180
Study: 15712772

Group type: EXPERIMENTAL
Intervention: New approach to teaching in CME programs
Number of subjects: 0
Study: 11257737

Group type: EXPERIMENTAL
Intervention: No antibiotic (n = 24)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: One dose of antibiotics (n = 35)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 5-day course of antibiotics (n = 31)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not receiving antibiotics)
Number of subjects: 108
Study: 9439944

Group type: EXPERIMENTAL
Intervention: Valproate (1 g per day) for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Flunarizine (10 mg per day) for 8 weeks
Number of subjects: 22
Study: 7944702

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ventricular fibrillation with intermittent ischemia
Number of subjects: 40
Study: 2827920

Group type: EXPERIMENTAL
Intervention: nedocromil sodium (1% nasal spray)
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 29079391

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fidelity strategies for intervention
Number of subjects: 0
Study: 28803502

Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine
Number of subjects: 352

Group type: COMPARATOR
Intervention: 20 µg recombinant hepatitis B vaccine
Number of subjects: 352
Study: 26646213

Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex ®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 22952303

Group type: EXPERIMENTAL
Intervention: Intervention ward
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control ward
Number of subjects: 152
Study: 21559935

Group type: EXPERIMENTAL
Intervention: Leptin levels in subjects with high Gleason Score (GS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Body fat mass
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Body composition and leptin relation to PCa aggressiveness
Number of subjects: 70

Group type: COMPARATOR
Intervention: Body mass index and percentage of body fat mass
Number of subjects: 70
Study: 18439560

Group type: EXPERIMENTAL
Intervention: Cataract surgery with combined primary posterior capsulorhexis and posterior optic buttonholing
Number of subjects: 50

Group type: COMPARATOR
Intervention: In‐the‐bag IOL implantation
Number of subjects: 50
Study: 16529860

Group type: EXPERIMENTAL
Intervention: Magnetic exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 24
Study: 15223814

Group type: EXPERIMENTAL
Intervention: Histamine (0.08 microg/kg/min, 0.16 microg/kg/min, 0.32 microg/kg/min)
Number of subjects: 14
Study: 10941943

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy
Number of subjects: 3703

Group type: COMPARATOR
Intervention: TURB alone
Number of subjects: 3703
Study: 9311953

Group type: EXPERIMENTAL
Intervention: Psyllium-enriched cereal
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control cereal (≤3 g soluble fiber/d)
Number of subjects: 404
Study: 1304806

Group type: EXPERIMENTAL
Intervention: Air-polishing unit
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pumice and water
Number of subjects: 46

Group type: COMPARATOR
Intervention: No cleaning
Number of subjects: 46
Study: 2859185

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg thrice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Felodipine 7.5 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30368489

Group type: EXPERIMENTAL
Intervention: Mobile application (app)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (treated as usual, without the app)
Number of subjects: 39
Study: 27897469

Group type: EXPERIMENTAL
Intervention: Standard care plus coaching
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 94
Study: 24717369

Group type: EXPERIMENTAL
Intervention: Raised C-reactive protein (CRP; >5 mg/L)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Early convalescence
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Convalescence
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Modified relative dose response values
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Prevalence of anemia and vitamin A deficiency
Number of subjects: 181
Study: 23189986

Group type: EXPERIMENTAL
Intervention: Hard gum shield‐aided intubation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Left paraglossal intubation
Number of subjects: 80
Study: 19946671

Group type: EXPERIMENTAL
Intervention: Floating platform mobile-bearing (MB) prosthesis (e.motion-FP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) prosthesis (Genesis II)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Floating platform mobile-bearing (MB) prosthesis (e.motion-FP) in FB-CR subgroup
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fixed-bearing cruciate retaining (FB-CR) prosthesis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Floating platform mobile-bearing (MB) prosthesis (e.motion-FP) in FB-PS subgroup
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fixed-bearing posteriorly stabilized (FB-PS) prosthesis
Number of subjects: 66
Study: 18279985

Group type: EXPERIMENTAL
Intervention: BodyFix (BF) system with abdominal compression
Number of subjects: 32

Group type: COMPARATOR
Intervention: VacLok (VL) immobilization device
Number of subjects: 32
Study: 16651498

Group type: EXPERIMENTAL
Intervention: Single follow-up clinic visit focusing on asthma self-monitoring and management, environmental modification and trigger control, and linkages and referrals to ongoing care.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Single follow-up clinic visit
Number of subjects: 488
Study: 14709290

Group type: EXPERIMENTAL
Intervention: topical betaxolol 0.5% solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 10870778

Group type: EXPERIMENTAL
Intervention: Single dose oral azithromycin 1 g
Number of subjects: 131

Group type: COMPARATOR
Intervention: Seven-day doxycycline 100 mg twice daily
Number of subjects: 131
Study: 9586517

Group type: EXPERIMENTAL
Intervention: Real Low-Level Laser therapy (830 nm Ga‐Al‐As Laser, 4 joules, 3 sessions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Real Low-Level Laser therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 8436152

Group type: EXPERIMENTAL
Intervention: Zabicipril 0.5 mg, 1 mg, or 2.5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3464039

Group type: COMPARATOR
Intervention: Ibuprofen (single dose)
Number of subjects: 0
Study: 29908319

Group type: EXPERIMENTAL
Intervention: Free vitamin D3 concentrations < 5pg/mL
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Free vitamin D3 concentrations 5 to 9pg/mL
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Free vitamin D3 concentrations > 9pg/mL
Number of subjects: 197
Study: 27965852

Group type: EXPERIMENTAL
Intervention: Theory-based educational intervention for chiropractors
Number of subjects: 150

Group type: COMPARATOR
Intervention: Printed copy of the guideline
Number of subjects: 150
Study: 23369009

Group type: EXPERIMENTAL
Intervention: Modified foot wear (sandal)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Modified plaster of Paris cast
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Scotchcast boot
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 22646524

Group type: EXPERIMENTAL
Intervention: Anti-alcohol message
Number of subjects: 84

Group type: COMPARATOR
Intervention: No alcohol message exposure
Number of subjects: 84
Study: 19941048

Group type: EXPERIMENTAL
Intervention: Telephone‐administered Cognitive‐Behavioral Therapy (T‐CBT)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Telephone‐administered Emotion‐Focused Therapy (T‐EFT)
Number of subjects: 127
Study: 18401810

Group type: EXPERIMENTAL
Intervention: 12-week exercise training program (resistance, flexibility, joint mobility, balance/coordination exercises)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 15986275

Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AM) alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AM) with 0.02% Mitomycin C (MMC)
Number of subjects: 23
Study: 14641605

Group type: EXPERIMENTAL
Intervention: Adenoidectomy before the age of 4 years
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Adenoidectomy at an early age
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Adenoidectomy due to recurrent otitis media
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Control group (children who underwent probing of the nasolacrimal duct)
Number of subjects: 1777
Study: 12585542

Group type: EXPERIMENTAL
Intervention: Data-dependent methods based on permutations of the data (ordinary least squares regression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data-dependent methods based on permutations of the data (least absolute deviations regression)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Data-dependent methods (six approaches)
Number of subjects: 0
Study: 10086671

Group type: EXPERIMENTAL
Intervention: 10 days of omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., and metronidazole 400 mg t.d.s. (OAM)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 10 days of omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., and metronidazole 400 mg t.d.s. (OAM) plus compliance enhancing measures
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups (OAM and OAM plus compliance enhancing measures)
Number of subjects: 119
Study: 7545889

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 133

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 133
Study: 1896092

Group type: EXPERIMENTAL
Intervention: 24,25-dihydroxyvitamin D3 (24,25(OH)2D3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 alpha-OH-D3 and calcium carbonate (existing treatment)
Number of subjects: 20
Study: 7013968

Group type: EXPERIMENTAL
Intervention: Haloperidol (Haldol)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Benzquinamide (Emetecon)
Number of subjects: 64
Study: 6367434

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg four times a day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28370958

Group type: EXPERIMENTAL
Intervention: Bottled spring water certified by Sri Lanka Standard (SLS) for a period of 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual drinking water
Number of subjects: 0
Study: 26590810

Group type: EXPERIMENTAL
Intervention: Phalangeal BMD measurement using a portable scanner
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Phalangeal BMD measurement
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Triage approach
Number of subjects: 121
Study: 24755124

Group type: EXPERIMENTAL
Intervention: FDC tablet with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: FDC tablet without food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDC tablets with normal dissolution characteristics
Number of subjects: 0

Group type: COMPARATOR
Intervention: FDC tablets with slower dissolution characteristics
Number of subjects: 0
Study: 23711168

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for pain and insomnia (CBT-PI)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for pain (CBT-P)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Education-only control (EOC)
Number of subjects: 367
Study: 20211222

Group type: EXPERIMENTAL
Intervention: Anti-cholinergic bronchodilator (ipratropium bromide)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18583205

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for bowel wall thickness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for bowel wall pattern
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for bowel wall blood flow
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for enlarged mesenteric lymph nodes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for abdominal free fluid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for mesenteric hypertrophy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for stenosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for fistula
Number of subjects: 20
Study: 16633103

Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6 g/d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG 16 billion/d for 15 d/mo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6 g/d + Lactobacillus casei DG 16 billion/d for 15 d/mo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 90
Study: 12505566

Group type: EXPERIMENTAL
Intervention: Intracoronary gamma radiation for ISR in SVGs
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Intracoronary gamma radiation for ISR in native coronary arteries
Number of subjects: 1142
Study: 11074833

Group type: EXPERIMENTAL
Intervention: Recurrent GABHS tonsillopharyngitis of the same serotype
Number of subjects: 60

Group type: COMPARATOR
Intervention: Initial GABHS infection
Number of subjects: 60
Study: 8930427

Group type: EXPERIMENTAL
Intervention: Regimen A (granules from a 30‐mg capsule mixed with apple juice and administered through a nasogastric tube)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regimen B (an intact 30‐mg capsule)
Number of subjects: 22
Study: 1528957

Group type: EXPERIMENTAL
Intervention: Imipramine plus Mianserin (30 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Imipramine alone (placebo control)
Number of subjects: 40
Study: 3987221

Group type: EXPERIMENTAL
Intervention: Controlled-release pseudoephedrine formulations
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Optimal controlled-release formulation from single-dose study
Number of subjects: 38

Group type: COMPARATOR
Intervention: Immediate-release pseudoephedrine hydrochloride
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference pseudoephedrine hydrochloride syrup
Number of subjects: 38
Study: 29555812

Group type: EXPERIMENTAL
Intervention: ACP decision support video
Number of subjects: 450